Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model - PubMed
3 days ago
- #organoid model
- #chemotherapy response
- #gastric cancer
- Study focuses on identifying molecular signatures affecting responses to first-line chemotherapy in gastric cancer (GC) using organoid models.
- 19 GC patient-derived organoids (PDOs) were created, mirroring parent tumor characteristics, and tested with five common chemotherapy regimens.
- PDOs were categorized into double-sensitive, single-sensitive, and not-sensitive groups based on treatment responses.
- Responsive PDOs showed high P53 pathway gene expression and low cell proliferative activity gene expression.
- A chemotherapy-based tumor classification for GC was developed and validated using TCGA dataset and public drug response data.
- Findings aim to enhance precision treatment strategies for GC by linking molecular signatures to chemotherapy efficacy.